{
  "docId": "019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "docSlug": "58255c61d2bdadc3239a5fe01efc41e1",
  "documentTitle": "BioNTech | Results Presentation Deck | 43 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 43,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "other",
  "function": "present_framework",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "Clinical trial design diagram showing randomization of 120 patients into three arms.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de071-5aa5-74ef-a452-60fcbf49cdc6/25",
  "deckHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "deckJsonHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6.json",
  "deckAnchorHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.48,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Randomization flow from patient population to three treatment arms",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe228ca6-c3fc-4952-a8f4-4b0149166345",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.7,
        "x": 0.07,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "PD1, Programmed cell death protein 1; R/R, refractory/relapsed; ORR, overall response rate; DoR, Duration of Response; DCR, disease control rate; TTR, time to response; PFS, progression free survival; OS, overall survival; PRO, patient reported outcomes",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75030658-74e6-4317-b887-52b7e63d16c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.65,
        "y": 0.18
      },
      "kind": "image",
      "text": "Global trial locations",
      "attrs": null,
      "subkind": "map",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7609176f-14b0-485f-ac2b-229b1eca856c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.6,
        "y": 0.68
      },
      "kind": "list",
      "text": "Primary Endpoints: Arm 1: ORR by RECIST 1.1; Secondary Endpoints: ORR, DOR, DCR, TTR, PFS, OS, safety, tolerability, PRO",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e287623-d421-4c73-af60-cef3f53baf33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.08,
        "y": 0.7
      },
      "kind": "list",
      "text": "Open-label, randomized Phase 2 trial; BNT111 and cemiplimab in combination or as single agents; Collaboration with Regeneron",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e224da32-4fee-48fa-9f7e-fd182cfb14e4",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.1,
        "x": 0.12,
        "y": 0.86
      },
      "kind": "metric",
      "text": "ORR 30%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "085733a3-5779-4c79-9ef3-c0bdb0c7d568",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.92,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "BNT111: Global Phase 2 Clinical Trial in Anti-PD1 R/R Melanoma Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8d50913-f80f-484d-a68b-e2b70e8a5382",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "1370a6af-4eb0-42f0-823d-7ea6711f680a",
      "evidence": "diagram/process: Randomization flow from patient population to three treatment arms",
      "confidence": 0.6
    }
  ],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "7c19ff75-59ce-4f4d-ae2e-5a4ecb71e915",
      "evidence": "Standardized representation of patient randomization and study arms",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 25,
      "from": 15,
      "beatId": "53c149a8-57e4-41f6-bcc6-f6d3b92e5c06",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The document presents BioNTech's product portfolio, including its COVID-19 vaccine and pipeline candidates",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 42,
      "from": 7,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6afc8369-9bbf-45e1-a77c-ba4d4e30b836",
      "evidence": "The document uses the Golden Circle framework to explain its vision, strategy, and achievements",
      "position": 0,
      "objective": "To explain why BioNTech's vision and strategy are important for the future of immunotherapy",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}